Dr. Moran provided a financial disclosure in his original submission letter. It states:
“This work was supported by a grant from Bayer Pharmaceuticals Corporation, West Haven,
Connecticut.” This statement, unfortunately, was not included with publication of
the original article.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Emergency MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Published online: July 19, 2007
Identification
Copyright
© 2007 Elsevier Inc. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Approaches to Treatment of Community-Acquired Pneumonia in the Emergency Department and the Appropriate Role of FluoroquinolonesJournal of Emergency MedicineVol. 33Issue 2
- PreviewGreg Moran is our colleague and friend and we believe that his professional and personal morals are beyond reproach. We are quite sure that he would disclose any relationships he has to the pharmaceutical industry on your journal’s conflict of interest form that is completed as part of the publication process. We are concerned, however, that your journal has failed to include these potential conflicts of interest with his article on community-acquired pneumonia (1). Given the importance of antibiotic choice in this disease and the strong links between antibiotics and the pharmaceutical industry, we think that this would be important information to provide to readers.
- Full-Text
- Preview
